

NHO 栃木医療センター 臨床研究部 加藤 徹 (2014.1.1～)

【研究業績】

治験

- ・第一三共エドキサバン 15mg 試験（心房細動治験）
- ・アストラゼネカ pEF 試験（心不全国際治験）

国立病院機構（NHO）循環器グループ 多施設共同研究

- ・ANOX 研究（代表：京都医療センター）
- ・EXCEED-J 研究（代表：京都医療センター）
- ・OPTION-CIN 研究（代表：横浜医療センター）
- ・PREHOSP 研究（代表：京都医療センター）
- ・禁煙外来 YOKUKANSAN 研究（代表：京都医療センター）
- ・禁煙外来管理栄養士介入研究（代表：京都医療センター）

その他の医師主導型 多施設共同研究

- ・VAL-THUNDER 研究（代表：獨協医科大学 井上教授）
- ・EXPAND 研究（代表：東北大学 下川教授）
- ・PRIZE 研究（代表：佐賀大学 野出教授）
- ・RESPECT-EPA 研究（代表：順天堂大学 代田教授）
- ・AFIRE 研究（代表：国立循環器病センター・熊本大学 小川教授）
- ・アピキサバン研究（代表：獨協医科大学 堀中教授）
- ・動脈硬化危険因子（代表：自治医科大学 小谷教授）
- ・禁煙外来・脂質異常研究（代表：国際医療福祉大学 梅田教授）
- ・歯周病研究（代表：当院歯科口腔外科 内山部長 / 自治医科大学 小谷教授）
- ・CHD 研究（代表：佐賀大学 野出教授 / 琉球大学 植田教授）
- ・ANAFIE 研究（代表：心臓血管研究所 山下武志院長）
- ・EXCITED-UA 研究（代表：獨協医科大学 井上教授）

【英文論文業績】

Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia

Hypertens Res. 2023 Mar;46(3):688-696.

IF=5.525

Randomized double-blind placebo-controlled multicenter trial for the effects of a polyherbal remedy, Yokukansan (YiganSan), in smokers with depressive tendencies

BMC Complementary Medicine and Therapies (2022) 22:311

IF: 2.838

Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol

PLOS One 2022 Nov 30;17(11):e0277766.

IF: 3.73

Cardiovascular Factors Associated with COVID-19 from an International Registry of Primarily Japanese Patients

Diagnosis. Sept 2022

IF: 3.992

Effects of High-Absorption Curcumin for the Prevention of Hypertensive Heart Disease: A Double-blind, Placebo-controlled, Randomised Clinical Study

European Heart Journal Open Aug 2022

Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study

Global Heart 17(1) June 2022

DOI: 10.5334/gh.1128

IF: 3.426

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study

Frontiers in Cardiovascular Medicine 9:882821 April 2022

DOI: 10.3389/fcvm.2022.882821

IF: 6.050

Association between serum urate level and carotid atherosclerosis: An insight from a post hoc analysis of the PRIZE randomised clinical trial

RMD Open 8(1):e002226 April 2022

DOI: 10.1136/rmdopen-2022-002226

IF: 5.117

Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study

Hypertension Research 45(4) February 2022

DOI: 10.1038/s41440-022-00857-9

IF: 3.872

Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial

PLoS ONE 17(1):e0261445 January 2022

DOI: 10.1371/journal.pone.0261445

IF: 3.730

Soluble Vascular Endothelial Growth Factor Receptor 2 and Prognosis in Patients with Chronic Heart Failure

Eur Soc Cardiol Heart Fail. 2022 (e-pub ahead of print)

IF: 4.411

Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED - J Study

J Am Heart Assoc. 11(3) January 2022

DOI: 10.1161/JAHA.121.023464

IF: 4.660

Usefulness of dual-axis rotational coronary angiography in primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction

Heart and Vessels 2021 DOI 10.1007/s00380-020-01738-2 ISSN 0910-8327

PMID: 33277662

IF: 1.618

Which is the best method in clinical practice for assessing improvement in vascular endothelial function after successful smoking cessation - Flow-mediated dilation (FMD) or reactive hyperemic peripheral arterial tonometry (RHPAT)?

Hypertens Res 2021 Jan;44(1):120-121. doi: 10.1038/s41440-020-00565-2. Epub 2020 Oct 22.

IF: 2.941

Impact of Smoking Status on Growth Differentiation Factor 15 and Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study
J Am Heart Assoc. 2020 Nov 10:e018217. doi: 10.1161/JAHA.120.018217.

Online ahead of print. PMID: 33170061

IF: 4.660

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial

PLoS Med. e1003095. Published online 2020 Apr 22. doi: 10.1371/journal.pmed.1003095

IF: 11.048

Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease.

J Am Heart Assoc.

2020;9:e015761. DOI: 10.1161/JAHA.119.015761

IF: 4.660

Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.

Drug Metabolism and Pharmacokinetics. 2020 Feb;35(1):151-159. doi: 10.1016/j.dmpk.2019.10.005.

IF: 1.874

VEGF-C and Mortality in Patients With Suspected or Known Coronary Artery Disease.

J Am Heart Assoc. 2018 Nov 6;7(21):e010355

IF: 4.660

The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.

Clin Exp Nephrol. 2018 Dec;22(6):1379-1386.

IF:1.971

Kampo extract goshuyuto as an option for preventive treatment of paroxysmal atrial fibrillation associated with migraine attacks.

Traditional and Kampo Medicine 2018; 5(2): 120-122.

Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.

Am J Med Sci. 2015 Sep;350(3):160-6.

IF:1.962

Docosahexaenoic Acid with a statin and endothelial function in patients with coronary artery disease.

J Atheroscler Thromb. 2015;22(5):440-1.

IF:3.478

Two-week administration of rivaroxaban resolved left atrial thrombus.

J Cardiol Cases. J Cardiol Cases

. 2014 Sep 26;10(6):238-240. doi: 10.1016/j.jccase.2014.08.006.

Therapeutic potential of α -glucosidase inhibitors to prevent postprandial endothelial dysfunction.

Int Heart J. 2014;55(5):386-90.

IF:2.226

Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function.

Hypertens Res. 2014 Jul;37(7):655-8.

IF:3.872